Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

729
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
729
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

756
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
756
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

669
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
669
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

780
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
780
Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

1.4K
Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide...
1.4K
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Which is the eligible patient to be treated with pioglitazone? The expert view.

Journal of endocrinological investigation·2012
Same author

Comparing the actions of older and newer therapies on body weight: to what extent should these effects guide the selection of antidiabetic therapy?

International journal of clinical practice·2010
Same author

Effects of early use of pioglitazone in combination with metformin in patients with newly diagnosed type 2 diabetes.

Current medical research and opinion·2007
Same author

Epidemiology and clinical presentation of type 2 diabetes.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2006
Same author

Nateglinide--current and future role in the treatment of patients with type 2 diabetes mellitus.

International journal of clinical practice·2005
Same author

The Clinical Significance of PPAR Gamma Agonism.

Current molecular medicine·2005
Same journal

Early retirement for consultants.

British medical journal (Clinical research ed.)·2010
Same journal

From COMAR: Essential troika of teaching, research, and clinical care.

British medical journal (Clinical research ed.)·2010
Same journal

Parliament's two way pull on the NHS.

British medical journal (Clinical research ed.)·2010
Same journal

Conference Report: After the summit.

British medical journal (Clinical research ed.)·2010
Same journal

Council election: South Western regional vacancy 1988-90.

British medical journal (Clinical research ed.)·2010
Same journal

Health managers support taxation based service.

British medical journal (Clinical research ed.)·2010
See all related articles

Related Experiment Video

Updated: Feb 26, 2026

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
06:59

Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

Published on: November 13, 2016

11.5K

Metformin and glibenclamide: comparative risks

I W Campbell

    British Medical Journal (Clinical Research Ed.)
    |August 4, 1984
    PubMed
    Summary

    No abstract available in PubMed .

    More Related Videos

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
    07:29

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

    Published on: June 20, 2015

    20.2K
    Improving IV Insulin Administration in a Community Hospital
    12:08

    Improving IV Insulin Administration in a Community Hospital

    Published on: June 11, 2012

    19.4K

    Related Experiment Videos

    Last Updated: Feb 26, 2026

    Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
    06:59

    Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test

    Published on: November 13, 2016

    11.5K
    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
    07:29

    Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies

    Published on: June 20, 2015

    20.2K
    Improving IV Insulin Administration in a Community Hospital
    12:08

    Improving IV Insulin Administration in a Community Hospital

    Published on: June 11, 2012

    19.4K